Akebia Therapeutics, Inc. Announces Initiation of Phase 2b Trial of Oral Anemia Candidate
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CINCINNATI--(BUSINESS WIRE)--Akebia Therapeutics, a biotech company focused on developing and commercializing small molecules to treat anemia and cancer, today announced that it has dosed the first patient in the Phase 2b trial of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD). AKB-6548 is an orally available, hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, which is designed to stabilize HIF2a, a critical regulator of red blood cell production and iron absorption. By working in this manner, AKB-6548 achieves a very controlled and natural stimulation of red blood cell production that is similar to the effect of modest increases in altitude.
Help employers find you! Check out all the jobs and post your resume.
CINCINNATI--(BUSINESS WIRE)--Akebia Therapeutics, a biotech company focused on developing and commercializing small molecules to treat anemia and cancer, today announced that it has dosed the first patient in the Phase 2b trial of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD). AKB-6548 is an orally available, hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, which is designed to stabilize HIF2a, a critical regulator of red blood cell production and iron absorption. By working in this manner, AKB-6548 achieves a very controlled and natural stimulation of red blood cell production that is similar to the effect of modest increases in altitude.
Help employers find you! Check out all the jobs and post your resume.